ArticleImmunology1995
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Article in Immunology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 104 citations in OpenAlex.
- In Vitro Characterization of an Equinized Anti-PD-L1 Antibody for Cancer Immunotherapy in Horses.Veterinary sciences · 2026Article
- FcγR binding differentially contributes to protection by two human monoclonal antibodies targetingScience translational medicine · 2025Article
- Impact of structural modifications of IgG antibodies on effector functions.Frontiers in immunology · 2023Review
- Logic-gated antibody pairs that selectively act on cells co-expressing two antigens.Nature biotechnology · 2022Article
- Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.Journal of hematology & oncology · 2020Article
- Antigen-Induced Allosteric Changes in a Human IgG1 Fc Increase Low-Affinity Fcγ Receptor Binding.Structure (London, England : 1993) · 2020Article
- Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.Frontiers in immunology · 2020Review
- Article
- Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection.Emerging microbes & infections · 2020Article
- Complement in malaria immunity and vaccines.Immunological reviews · 2020Review
- A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.Cell · 2019Article
- Mind the Gap: How Interspecies Variability in IgG and Its Receptors May Complicate Comparisons of Human and Non-human Primate Effector Function.Frontiers in immunology · 2019Review
- A single residue switch reveals principles of antibody domain integrity.The Journal of biological chemistry · 2018Article
- ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile.PloS one · 2018Article
- Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey.PloS one · 2018Article
- Precision glycocalyx editing as a strategy for cancer immunotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.Molecular immunology · 2015Article
- Basigin is a druggable target for host-oriented antimalarial interventions.The Journal of experimental medicine · 2015Article
- Cynomolgus and pigtail macaque IgG subclasses: characterization of IGHG genes and computational analysis of IgG/Fc receptor binding affinity.Immunogenetics · 2014Article
- IgG subclasses and allotypes: from structure to effector functions.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have found that amino acid residues necessary for C1q and Fc gamma R binding of human IgG1 are located in the N-terminal region of the CH2 domain, residues 231-238, using a matched set of engineered antibodies based on the anti-HLA-DR antibody L243. Changing the leucine 235 in the CH2 region of IgG3 and IgG4 to glutamic acid was already known to abolish Fc gamma RI binding. We have confirmed this for IgG1 and also found a concomitant abolition of human complement lysis with retention of Fc gamma RIII-mediated function. Changing the glycine at 237 to alanine of IgG1 also abolished Fc gamma RI binding and reduced human complement lysis and Fc gamma RIII-mediated function. Exchanging the whole region 233-236 with the sequence found in human IgG2, abolished Fc gamma RI binding and human complement lysis and reduced Fc gamma RIII-mediated function of IgG1. In contrast, a change in the previously described C1q-binding motif, from lysine at 320 to alanine, had no effect on IgG1-mediated complement lysis.
Indexed as
Identifiers
7490135PMC1384012W1571049310What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.